The latest price target for CervoMed (NASDAQ:CRVO) was reported by D. Boral Capital on February 19, 2025. The analyst firm set a price target for $10.00 expecting CRVO to rise to within 12 months (a possible 338.58% upside). 17 analyst firms have reported ratings in the last year.

The latest analyst rating for CervoMed (NASDAQ:CRVO) was provided by D. Boral Capital, and CervoMed upgraded their buy rating.

The last upgrade for CervoMed Inc happened on February 19, 2025 when D. Boral Capital raised their price target to $10. D. Boral Capital previously had a hold for CervoMed Inc.

The last downgrade for CervoMed Inc happened on December 17, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for CervoMed Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CervoMed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CervoMed was filed on February 19, 2025 so you should expect the next rating to be made available sometime around February 19, 2026.

While ratings are subjective and will change, the latest CervoMed (CRVO) rating was a upgraded with a price target of $0.00 to $10.00. The current price CervoMed (CRVO) is trading at is $2.28, which is within the analyst’s predicted range.